{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T10:50:59Z","timestamp":1792752659309,"version":"4.5.0"},"reference-count":65,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2023.12054","type":"journal-article","created":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T08:51:21Z","timestamp":1685609481000},"source":"Crossref","is-referenced-by-count":34,"title":["Therapeutic management of atypical antipsychotic\u2011related metabolic dysfunctions using GLP\u20111 receptor agonists: A systematic review"],"prefix":"10.3892","volume":"26","author":[{"given":"Octavian","family":"Vasiliu","sequence":"first","affiliation":[{"name":"Department of Psychiatry, 'Dr. Carol Davila' University Emergency Central Military Hospital, 010816 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2023,6,1]]},"reference":[{"key":"key20230710064600_b1-ETM-26-1-12054","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s40265-020-01393-x","article-title":"Pharmacological management of glucose dysregulation in patients treated with second-generation antipsychotics","volume":"80","author":"Cernea","year":"2020","journal-title":"Drugs"},{"issue":"e19590","key":"key20230710064600_b2-ETM-26-1-12054","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0019590","article-title":"Life expectancy at birth for people with serious mental illness and other major disorders from a secondary mental health care case register in London","volume":"6","author":"Chang","year":"2011","journal-title":"PLoS One"},{"key":"key20230710064600_b3-ETM-26-1-12054","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jad.2015.03.027","article-title":"Causes of decreased life expectancy over the life span in bipolar disorder","volume":"180","author":"Kessing","year":"2015","journal-title":"J Affect Disord"},{"key":"key20230710064600_b4-ETM-26-1-12054","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1093\/schbul\/sbw028","article-title":"Somatic comorbidity in schizophrenia: Some possible biological mechanisms across the life span","volume":"42","author":"Dieset","year":"2016","journal-title":"Schizophr Bull"},{"issue":"CXXI","key":"key20230710064600_b5-ETM-26-1-12054","first-page":"25","article-title":"Analysis of risk factors for antipsychotic-resistant schizophrenia in young patients-a retrospective analysis","author":"Vasiliu","year":"2018","journal-title":"Rom J Mil Med"},{"key":"key20230710064600_b6-ETM-26-1-12054","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1176\/appi.ajp.2016.16040442","article-title":"Endogenous and antipsychotic-related risks for diabetes mellitus in young people with schizophrenia: A Danish population-based cohort study","volume":"174","author":"Rajkumar","year":"2017","journal-title":"Am J Psychiatry"},{"key":"key20230710064600_b7-ETM-26-1-12054","first-page":"26","article-title":"Therapeutic management of schizophrenia and substance use disorders dual diagnosis-clinical vignettes","volume":"121","author":"Vasiliu","year":"2018","journal-title":"Rom J Mil Med"},{"issue":"92","key":"key20230710064600_b8-ETM-26-1-12054","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-10-92","article-title":"Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: Potential physiological benefits","volume":"10","author":"Ebdrup","year":"2012","journal-title":"BMC Med"},{"key":"key20230710064600_b9-ETM-26-1-12054","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.schres.2018.09.019","article-title":"GLP-1 agonists for metabolic disorders in schizophrenia","volume":"204","author":"Kouidrat","year":"2019","journal-title":"Schizophr Res"},{"issue":"111","key":"key20230710064600_b10-ETM-26-1-12054","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2023.11810","article-title":"Esketamine for treatment-resistant depression: A review of clinical evidence (Review)","volume":"25","author":"Vasiliu","year":"2023","journal-title":"Exper Ther Med"},{"key":"key20230710064600_b11-ETM-26-1-12054","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.3892\/etm.2019.7285","article-title":"Effects of olanzapine on cytokine profile and brain-derived neurotrophic factor in drug-na\u00efve subjects with first-episode psychosis","volume":"17","author":"Hatziagelaki","year":"2019","journal-title":"Exp Ther Med"},{"issue":"880568","key":"key20230710064600_b12-ETM-26-1-12054","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.880568","article-title":"Immune system abnormalities in schizophrenia: An integrative view and translational perspectives","volume":"13","author":"Ermakov","year":"2022","journal-title":"Front Psychiatry"},{"key":"key20230710064600_b13-ETM-26-1-12054","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1093\/ijnp\/pyaa097","article-title":"Mechanisms underlying the comorbidities of schizophrenia and type 2 diabetes mellitus","volume":"24","author":"Mizuki","year":"2021","journal-title":"Int J Neuropsychopharmacol"},{"issue":"623681","key":"key20230710064600_b14-ETM-26-1-12054","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.623681","article-title":"The burden of antipsychotic-induced weight gain and metabolic syndrome in children","volume":"12","author":"Libowitz","year":"2021","journal-title":"Front Psychiatry"},{"issue":"643","key":"key20230710064600_b15-ETM-26-1-12054","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2017.00643","article-title":"Molecular mechanisms of antipsychotic drug-induced diabetes","volume":"11","author":"Chen","year":"2017","journal-title":"Front Neurosci"},{"issue":"7092","key":"key20230710064600_b16-ETM-26-1-12054","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23137092","article-title":"Crosstalk between schizophrenia and metabolic syndrome: The role of oxytocinergic dysfunction","volume":"23","author":"Goh","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"186","key":"key20230710064600_b17-ETM-26-1-12054","doi-asserted-by":"publisher","DOI":"10.1186\/s40814-018-0378-1","article-title":"Reducing weight gain in people with schizophrenia, schizoaffective disorder, and first episode psychosis: Describing the process of developing the Structured lifestyle Education for People with SchizophrEnia (STEPWISE) intervention","volume":"4","author":"Carey","year":"2018","journal-title":"Pilot Feasibility Stud"},{"issue":"210","key":"key20230710064600_b18-ETM-26-1-12054","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2020.9340","article-title":"Predictive factors in early onset schizophrenia","volume":"20","author":"Budisteanu","year":"2020","journal-title":"Exp Ther Med"},{"issue":"125","key":"key20230710064600_b19-ETM-26-1-12054","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2023.11824","article-title":"Impact of SGLT2 inhibitors on metabolic status in patients with psychiatric disorders undergoing treatment with second-generation antipsychotics (Review)","volume":"25","author":"Vasiliu","year":"2023","journal-title":"Exp Ther Med"},{"key":"key20230710064600_b20-ETM-26-1-12054","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ebmental-2021-300291","article-title":"Metformin in the management of antipsychotic-induced weight gain in adults with psychosis: Development of the first evidence-based guideline using GRADE methodology","volume":"25","author":"Fitzgerald","year":"2022","journal-title":"Evid Based Ment Health"},{"issue":"19r02483","key":"key20230710064600_b21-ETM-26-1-12054","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.19r02483","article-title":"Effectiveness of pharmacologic interventions in the management of weight gain in patients with severe mental illness: A systematic review and meta-analysis","volume":"21","author":"Hiluy","year":"2019","journal-title":"Prim Care Companion CNS Disord"},{"key":"key20230710064600_b22-ETM-26-1-12054","doi-asserted-by":"publisher","first-page":"E1101","DOI":"10.1152\/ajpendo.00309.2020","article-title":"GLP1 receptor agonism protects against acute olanzapine-induced hyperglycemia","volume":"319","author":"Medak","year":"2020","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"key20230710064600_b23-ETM-26-1-12054","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.pnpbp.2010.04.024","article-title":"A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model","volume":"34","author":"Boyda","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"key20230710064600_b24-ETM-26-1-12054","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1097\/JCP.0b013e318184b4c5","article-title":"Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration","volume":"28","author":"Chintoh","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"key20230710064600_b25-ETM-26-1-12054","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1177\/0269881115625496","article-title":"Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes","volume":"30","author":"Mayfield","year":"2016","journal-title":"J Psychopharmacol"},{"key":"key20230710064600_b26-ETM-26-1-12054","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1001\/jamapsychiatry.2017.3053","article-title":"Liraglutide for the treatment of antipsychotic drug-induced weight gain","volume":"74","author":"Deutch","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"key20230710064600_b27-ETM-26-1-12054","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1210\/en.2014-1675","article-title":"Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain","volume":"156","author":"Heppner","year":"2015","journal-title":"Endocrinolog"},{"key":"key20230710064600_b28-ETM-26-1-12054","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1007\/s12020-021-02945-1","article-title":"Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: A meta-analysis","volume":"75","author":"Zhong","year":"2022","journal-title":"Endocrine"},{"key":"key20230710064600_b29-ETM-26-1-12054","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1111\/dom.13899","article-title":"Oral semaglutide for type 2 diabetes: A systematic review and meta-analysis","volume":"22","author":"Avgerinos","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"key20230710064600_b30-ETM-26-1-12054","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s40265-015-0370-5","article-title":"Albiglutide: A review of its use in patients with type 2 diabetes mellitus","volume":"75","author":"Blair","year":"2015","journal-title":"Drugs"},{"key":"key20230710064600_b31-ETM-26-1-12054","doi-asserted-by":"publisher","first-page":"433","DOI":"10.2147\/DMSO.S193693","article-title":"Comparative effectiveness of long-acting GLP-1 receptor agonists in type-2 diabetes: A short review on the emerging data","volume":"13","author":"Chudleigh","year":"2020","journal-title":"Diabetes Metab Syndr Obes"},{"key":"key20230710064600_b32-ETM-26-1-12054","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.2337\/dc13-2759","article-title":"Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3)","volume":"37","author":"Umpierrez","year":"2014","journal-title":"Diabetes Care"},{"key":"key20230710064600_b33-ETM-26-1-12054","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/dom.12596","article-title":"Review of head-to-head comparison of glucagon-like peptide-1 receptor agonists","volume":"18","author":"Madsbad","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"key20230710064600_b34-ETM-26-1-12054","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.aprim.2016.06.009","article-title":"Lixisenatide in patients with type 2 diabetes and obesity: Beyond glycamic control","volume":"49","author":"Roca-Rodriguez","year":"2017","journal-title":"Aten Primaria"},{"key":"key20230710064600_b35-ETM-26-1-12054","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.2337\/dc12-2709","article-title":"Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X)","volume":"36","author":"Rosenstock","year":"2013","journal-title":"Diabetes Care"},{"key":"key20230710064600_b36-ETM-26-1-12054","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/dom.12076","article-title":"Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin","volume":"15","author":"Kapitza","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"key20230710064600_b37-ETM-26-1-12054","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/acps.12711","article-title":"No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia","volume":"136","author":"Ish\u00f8y","year":"2017","journal-title":"Acta Psychiatr Scand"},{"key":"key20230710064600_b38-ETM-26-1-12054","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1111\/dom.13167","article-title":"Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: A randomized controlled trial (CODEX)","volume":"20","author":"Siskind","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"key20230710064600_b39-ETM-26-1-12054","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/dom.12849","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis","volume":"19","author":"Htike","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"key20230710064600_b40-ETM-26-1-12054","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s13300-020-00981-0","article-title":"The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: The SURPASS clinical trials","volume":"12","author":"Min","year":"2021","journal-title":"Diabetes Ther"},{"key":"key20230710064600_b41-ETM-26-1-12054","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): A randomized, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"Lancet"},{"key":"key20230710064600_b42-ETM-26-1-12054","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/j.1398-9995.2010.02530.x","article-title":"Grading quality of evidence and strength of recommendations in clinical practice guidelines part 3 of 3. The GRADE approach to developing recommendations","volume":"66","author":"Brozek","year":"2011","journal-title":"Allergy"},{"key":"key20230710064600_b43-ETM-26-1-12054","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jclinepi.2015.11.017","article-title":"A guide for health professionals to interpret and use recommendations in guidelines developed with the GRADE approach","volume":"72","author":"Neumann","year":"2016","journal-title":"J Clin Epidemiol"},{"issue":"n71","key":"key20230710064600_b44-ETM-26-1-12054","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"key20230710064600_b45-ETM-26-1-12054","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1177\/1049732312452938","article-title":"Beyond PICO: The SPIDER tool for qualitative evidence synthesis","volume":"22","author":"Cooke","year":"2012","journal-title":"Qual Health Res"},{"key":"key20230710064600_b46-ETM-26-1-12054","author":"Sch\u00fcnemann"},{"key":"key20230710064600_b47-ETM-26-1-12054","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1177\/0269881118756061","article-title":"Liraglutide prevents metabolic side-effects and improves recognition and working memory during antipsychotic treatment in rats","volume":"32","author":"Babic","year":"2018","journal-title":"J Psychopharmacol"},{"key":"key20230710064600_b48-ETM-26-1-12054","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.schres.2008.05.011","article-title":"The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance","volume":"103","author":"Lykkegaard","year":"2008","journal-title":"Schizophr Res"},{"key":"key20230710064600_b49-ETM-26-1-12054","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1176\/appi.ajp.2013.12101344","article-title":"Sustained weight loss after treatment with a glucagon-like peptide-1 receptor agonist in an obese patient with schizophrenia and type 2 diabetes","volume":"170","author":"Ish\u00f8y","year":"2013","journal-title":"Am J Psychiatry"},{"key":"key20230710064600_b50-ETM-26-1-12054","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1177\/0004867416636243","article-title":"Weight loss associated with exenatide in an obese man with diabetes commenced on clozapine","volume":"50","author":"Siskind","year":"2016","journal-title":"Aust N Z J Psychiatry"},{"key":"key20230710064600_b51-ETM-26-1-12054","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1001\/jamapsychiatry.2017.1220","article-title":"Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: A randomized clinical trial","volume":"74","author":"Larsen","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"key20230710064600_b52-ETM-26-1-12054","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/acps.12982","article-title":"One-year follow-up on liraglutide treatment for prediabetes and overweight\/obesity in clozapine- or olanzapine-treated patients","volume":"139","author":"Svensson","year":"2019","journal-title":"Acta Psychiatr Scand"},{"issue":"S248","key":"key20230710064600_b53-ETM-26-1-12054","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2020.02.015","article-title":"T44. 12-Month follow-up of metabolic measures following a randomised controlled trial of treatment of clozapine associated obesity and diabetes with exenatide (CODEX)","volume":"46 (Suppl.1)","author":"Siskind","year":"2020","journal-title":"Schizophr Bull"},{"key":"key20230710064600_b54-ETM-26-1-12054","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/dom.12795","article-title":"Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: A randomized, placebo-controlled trial","volume":"19","author":"Ish\u00f8y","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"key20230710064600_b55-ETM-26-1-12054"},{"key":"key20230710064600_b56-ETM-26-1-12054","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1111\/dom.14334","article-title":"The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: Results of a pilot randomized, double-blind, placebo-controlled trial","volume":"23","author":"Whicher","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"19m02504","key":"key20230710064600_b57-ETM-26-1-12054","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.19m02504","article-title":"Glucagon-like peptide analogs are superior for diabetes and weight control in patients on antipsychotic medications: A retrospective cohort study","volume":"22","author":"Perlis","year":"2020","journal-title":"Prim Care Companion CNS Disord"},{"issue":"113830","key":"key20230710064600_b58-ETM-26-1-12054","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2021.113830","article-title":"Effect of liraglutide 3.0 mg treatment on weight reduction in obese antipsychotic-treated patients","volume":"299","author":"Lee","year":"2021","journal-title":"Psychiatry Res"},{"key":"key20230710064600_b59-ETM-26-1-12054","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/dom.13522","article-title":"Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis","volume":"21","author":"Siskind","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"key20230710064600_b60-ETM-26-1-12054","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1177\/02698811211035391","article-title":"Efficacy and tolerability of pharmacological interventions on metabolic disturbances induced by atypical antipsychotics in adults: A systematic review and network meta-analysis","volume":"35","author":"Wang","year":"2021","journal-title":"J Psychopharmacol"},{"key":"key20230710064600_b61-ETM-26-1-12054","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1177\/0269881116645254","article-title":"BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment","volume":"30","author":"Cooper","year":"2016","journal-title":"J Psychopharmacol"},{"key":"key20230710064600_b62-ETM-26-1-12054"},{"key":"key20230710064600_b63-ETM-26-1-12054","first-page":"19","article-title":"The glucagon like peptide-1 analogue dulaglutide to prevent antipsychotic induced weight gain-a study protocol proposal","volume":"5","author":"Sailer","year":"2019","journal-title":"Prin Pract Clin Res"},{"key":"key20230710064600_b64-ETM-26-1-12054"},{"issue":"102427","key":"key20230710064600_b65-ETM-26-1-12054","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2022.102427","article-title":"Adverse drug reactions of GLP-1 agonists: A systematic review of case reports","volume":"16","author":"Shetty","year":"2022","journal-title":"Diabetes Metab Syndr"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T02:46:17Z","timestamp":1688957177000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2023.12054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,1]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,6,1]]}},"URL":"https:\/\/doi.org\/10.3892\/etm.2023.12054","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,1]]},"article-number":"355"}}